High cholesterol, a serious risk factor for heart disease, can affect both men and women, and it's common for cholesterol levels to rise with age. But it's often a problem for men earlier in life than for women.
All news from Palliative Medicine
Researchers at the University of Arizona have discovered that metformin, a drug commonly used to treat type 2 diabetes, might also be used to treat heart failure with preserved ejection fraction (HFpEF), a condition that is predicted to affect over 8% of people ages 65 or older by the year 2020.
Globally, one in four people over age 25 is at risk for stroke during their lifetime, according to a new scientific study. Researchers found a nearly five-fold difference in lifetime stroke risk worldwide, with the highest risk in East Asia and Central and Eastern Europe, and lowest in sub-Saharan Africa.
Three papers from research teams led by a Massachusetts General Hospital (MGH) physician examine the current readiness of U.S. emergency departments (EDs) to care for children and describe an initiative that led to the appointment of a Pediatric Emergency Care Coordinator (PECC) – a step considered the single best intervention to improve pediatric emergency care – in all Massachusetts EDs.
Doctors may be able to assess the survival rates of melanoma patients following the discovery of a molecule that allows cancer to spread from the skin to other parts of the body.
Extremely obese people are needing a far higher dose of radiation during x-ray examinations than people of normal weight, increasing their risk of cancer, new research has shown.
In this study, sulfated polysaccharide-rich extracts were isolated from 22 tropical seaweeds (4 red, 11 brown, and 7 green) found in northeastern Brazil, and evaluated for the role of anticoagulant agents.
A recent study led by researchers in Texas A&M University's department of nutrition and food science shows how a novel regulatory mechanism serves as an important biomarker for the development of diabetes, as well as a potential therapeutic target for its prevention.
Myelofibrosis is a severe and very rare hematological disease for which treatment has only been partially effective to date. Its low incidence rate is one of the reasons why effective therapies are still lacking.